Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's CT-388?
CT-388 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Type 2 Diabetes. According to...